[go: up one dir, main page]

HUP0103573A2 - Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest - Google Patents

Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest

Info

Publication number
HUP0103573A2
HUP0103573A2 HU0103573A HUP0103573A HUP0103573A2 HU P0103573 A2 HUP0103573 A2 HU P0103573A2 HU 0103573 A HU0103573 A HU 0103573A HU P0103573 A HUP0103573 A HU P0103573A HU P0103573 A2 HUP0103573 A2 HU P0103573A2
Authority
HU
Hungary
Prior art keywords
von willebrand
willebrand factor
immunoglobulins
monoclonal antibody
humanized anti
Prior art date
Application number
HU0103573A
Other languages
English (en)
Inventor
Man Sung Co
Maximiliano Vasquez
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of HUP0103573A2 publication Critical patent/HUP0103573A2/hu
Publication of HUP0103573A3 publication Critical patent/HUP0103573A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát képezik von Willebrand faktor elleni, humanizáltimmunglobulinok (mint például monoklonális antitestek); az egéreredetűAJvW-2 antitest humanizált formái; az immunglobulinokat kódolópolinukleotid-szekvenciák; az immunglobulinok előállítására szolgálóeljárás; az immunglobulinokat aktív összetevőként tartalmazógyógyászati készítmények; az antitestet aktív összetevőként tartalmazóterápiás hatóanyag trombózisos betegségek kezelésére; eljárások ebetegségek kezelésére. Ó
HU0103573A 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody HUP0103573A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/136,315 US6228360B1 (en) 1998-08-19 1998-08-19 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
PCT/US1999/016724 WO2000010601A1 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Publications (2)

Publication Number Publication Date
HUP0103573A2 true HUP0103573A2 (hu) 2002-01-28
HUP0103573A3 HUP0103573A3 (en) 2003-09-29

Family

ID=22472317

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103573A HUP0103573A3 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Country Status (17)

Country Link
US (4) US6228360B1 (hu)
EP (1) EP1112085B1 (hu)
JP (1) JP4590734B2 (hu)
KR (1) KR100693260B1 (hu)
CN (1) CN1259972C (hu)
AT (1) ATE476989T1 (hu)
AU (1) AU766500B2 (hu)
BR (1) BR9913084A (hu)
CA (1) CA2340466A1 (hu)
DE (1) DE69942668D1 (hu)
HU (1) HUP0103573A3 (hu)
IL (2) IL141158A0 (hu)
NO (1) NO20010747L (hu)
NZ (1) NZ509536A (hu)
RU (1) RU2223785C2 (hu)
WO (1) WO2000010601A1 (hu)
ZA (1) ZA200100939B (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
WO2003032907A2 (en) * 2001-10-16 2003-04-24 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
JPWO2004011030A1 (ja) * 2002-07-29 2005-11-24 味の素株式会社 血小板減少症治療用医薬組成物
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
BRPI0508862A (pt) * 2004-03-15 2007-09-04 Biogen Idec Inc métodos e construtos para expressar multìmeros de polipeptìdios em células eucarióticas utilizando junção alternativa
CN1997385B (zh) * 2004-04-15 2012-01-11 阿瑟拉生物技术公司 膜联蛋白v用于预防动脉血栓和斑块破裂
CA2579374A1 (en) * 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
EP1853630A1 (en) * 2004-10-22 2007-11-14 Applied Molecular Evolution Inc. Methods of optimizing antibody variable region binding affinity
PL1836500T3 (pl) * 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
LT2444424T (lt) * 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2252303A2 (en) * 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2751424A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
US10544231B2 (en) * 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
HUT67943A (en) * 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
WO1996017078A1 (fr) * 1994-11-30 1996-06-06 Ajinomoto Co., Inc. Agent antithrombotique et anticorps monoclonaux contre le facteur de von willebrand
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Also Published As

Publication number Publication date
CN1311691A (zh) 2001-09-05
AU5668099A (en) 2000-03-14
EP1112085A1 (en) 2001-07-04
NO20010747D0 (no) 2001-02-14
US20050197494A1 (en) 2005-09-08
US7311913B2 (en) 2007-12-25
HUP0103573A3 (en) 2003-09-29
RU2223785C2 (ru) 2004-02-20
US7138116B2 (en) 2006-11-21
US20030180293A1 (en) 2003-09-25
JP2002523379A (ja) 2002-07-30
IL141158A0 (en) 2002-02-10
JP4590734B2 (ja) 2010-12-01
NZ509536A (en) 2002-11-26
US6228360B1 (en) 2001-05-08
ATE476989T1 (de) 2010-08-15
AU766500B2 (en) 2003-10-16
IL141158A (en) 2006-04-10
KR100693260B1 (ko) 2007-03-13
CA2340466A1 (en) 2000-03-02
US20030064068A1 (en) 2003-04-03
BR9913084A (pt) 2001-05-08
EP1112085B1 (en) 2010-08-11
DE69942668D1 (de) 2010-09-23
EP1112085A4 (en) 2002-11-20
WO2000010601A1 (en) 2000-03-02
NO20010747L (no) 2001-04-03
CN1259972C (zh) 2006-06-21
US6613328B2 (en) 2003-09-02
ZA200100939B (en) 2001-09-03
KR20010072749A (ko) 2001-07-31

Similar Documents

Publication Publication Date Title
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
ATE223413T1 (de) Neuartige verbindungen
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
DE69429095D1 (de) Humanisierte antikoerper
ATE215831T1 (de) Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
GB9715177D0 (en) Medicament
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline